Quantum Biopharma (QNTM) Expected to Announce Quarterly Earnings on Friday

Quantum Biopharma (NASDAQ:QNTM) will likely be announcing its results after the market closes on Friday, May 8th. Analysts expect the company to announce earnings of ($0.4904) per share and revenue of $3.74 million for the quarter.

Quantum Biopharma (NASDAQ:QNTM) last released its earnings results on Thursday, March 26th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.49).

Quantum Biopharma Stock Performance

QNTM opened at $5.36 on Wednesday. The firm has a market cap of $20.48 million, a P/E ratio of -0.61 and a beta of 0.29. Quantum Biopharma has a 52-week low of $2.07 and a 52-week high of $38.25. The business’s fifty day moving average is $3.62 and its 200-day moving average is $6.48.

Analyst Ratings Changes

Several analysts have recently issued reports on QNTM shares. Wall Street Zen raised Quantum Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Quantum Biopharma in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Quantum Biopharma has an average rating of “Sell”.

Institutional Trading of Quantum Biopharma

An institutional investor recently bought a new position in Quantum Biopharma stock. Virtu Financial LLC acquired a new stake in Quantum Biopharma Ltd. (NASDAQ:QNTM) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 10,406 shares of the company’s stock, valued at approximately $76,000. Virtu Financial LLC owned approximately 0.27% of Quantum Biopharma as of its most recent SEC filing. Institutional investors and hedge funds own 1.24% of the company’s stock.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.